Effect of amantadine hydrochloride on symptoms of frontal lobe dysfunction in brain injury: Case studies and review

Journal of Neuropsychiatry and Clinical Neurosciences

Volumn 9, Issue 2, 1997, Pages 222-230

  Kraus, Marilyn F ^a,b   Maki, Pauline M ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; DOPAMINE RECEPTOR STIMULATING AGENT;

ADULT; ARTICLE; ATTENTION; BRAIN DYSFUNCTION; BRAIN INJURY; CLINICAL ARTICLE; COGNITIVE DEFECT; DRUG EFFICACY; FEMALE; FRONTAL LOBE; HUMAN; IMPULSIVENESS; MALE; MENINGITIS; MOTIVATION; MUSCLE TWITCH; NAUSEA; NEUROPSYCHIATRY; NEUROPSYCHOLOGICAL TEST; PARANASAL SINUS; PLANNING; PRIORITY JOURNAL; PROBLEM SOLVING; SHORT TERM MEMORY; SYMPTOM; VERTIGO;

EID: 0030994602     PISSN: 08950172     EISSN: None     Source Type: Journal    
DOI: 10.1176/jnp.9.2.222     Document Type: Article

References (39)

1. Interagency Head Injury Task Force Report: National Institute of Neurological Disorders and Stroke. Bethesda, MD, National Institutes of Health, February 1989
2. Vecht CJ, Van Woekom TCAM, Teelken AW, et al: Homovanillic acid and 5-hydroxyindoleacetic acid cerebrospinal fluid levels. Arch Neurol 1975; 32: 792-797
3. Pearlson GD, Robinson RG: Suction lesions of the frontal cerebral cortex in the rat induce asymmetrical behavioral and catechommergic responses. Brain Res 1981; 218:233-242
4. Brown RM, Crane AM, Goldman PS: Regional distribution of monoamines in the cerebral cortex and subcortical structures of the rhesus monkey: concentrations and in vivo synthesis rates, Brain Res 1979; 168:133-150
5. Levin H, Williams D, Eisenberg H, et al: Serial magnetic resonance imaging and neurobehavioral findings after mild to moderate closed head injury. J Neurol Neurosurg Psychiatry 1992; 55:255-262
6. Levin H, Kraus MF: The frontal lobes and traumatic brain injury. J Neuropsychiatry Clin Neurosci 1994; 6:443-454
7. Herrman EC, Grabliks J, Engle C, et al: Antiviral activity of L-adamantanamine (amantadine). Proc Soc Exp Biol Med 1960; 103:625
8. Schwab RS, England AC, Postkanzer DC, et al: Amantadine in the treatment of Parkinsons disease. JAMA 1969; 208:1168-1170
9. Aoki F, Sitar D: Clinical pharmacokinetics of amantadine hydrochloride. Clin Pharmacokinet 1988; 14:35-51
10. Gianutsos G, Stewart C, Dunn JP: Pharmacologic changes in dopaminergic systems induced by long-term administration of amantadine. Eur J Pharmacol 1985; 110:357-361
11. Allen RM: Role of amantadine in the management of neuroleptic-induced extrapyramidal syndromes: overview and pharmacology. Clin Neuropharmacol 1983; 6(suppl 1):S64-S73
12. Weller M, Kornhuber J: A rationale for NMDA receptor antagonist therapy of the neuroleptic malignant syndrome. Med Hypotheses 1992; 38:329-333
13. Gualtieri T, Chandler M, Coons, Brown L: Amantadine: a new clinical profile for traumatic brain injury. Clin Neuropharmacol 1989; 12:258-270
14. Van Reekum R, Bayley M, Garner S, et al: N of 1 study: amantadine for the amotivational syndrome in a patient with traumatic brain injury. Brain Injury 1995; 9:49-53
15. Andersson S, Berstad J, Finset A, et al: Amantadine in cognitive failure in patients with traumatic head injuries. Tidsskrift for den Norske Lägeforening 1992; 112:2070-2072
16. Nickels JL, Schneider WN, Dombovy ML, et al: Clinical use of amantadine in brain injury rehabilitation. Brain Inj 1994; 8:709-718
17. Erkulwater S, Pillai R: Amantadine and the end stage dementia of Alzheimer's type. South Med J 1989; 82:550-554
18. Muller H, Dastoor D, Kingner A, et al: Amantadine in senile dementia: electroencephalographic and clinical effects. J Am Geriatr Soc 1979; 27:9
19. Roca RP, Santmyer K, Gloth M, et al: Improvements in activity and appetite among long-term care patients treated with amantadine. J Am Geriatr Soc 1990; 38:675-677
20. Semlitsch HV, Anderer P, Saletu B: Topographic mapping of long latency "cognitive" event-related potentials (P300): a double-blind, placebo-controlled study with amantadine in mild dementia. J Neural Transm 1992; 4:319-336
21. Suitsu N: A computer assisted EEG study on psychotropic properties of antiparkinson's drugs. Seishin Shinkeigaku Zasshi 1992; 94:238-262
22. Moryl E, Danysz W, Quack G: Potential antidepressive properties of amantadine, memantine and bifemelane. Pharmacol Toxicol 1993; 72:394-397
23. Murray TJ: Amantadine therapy for fatigue in multiple sclerosis. Can J Neurol Sci 1985; 12:251-254
24. Horiguchi J, Inami Y, Shoda T: Effects of long-term amantadine treatment on clinical symptoms and EEG of a patient in a vegetative state. Clin Neuropharmacol 1990; 13:84-88
25. Shahar E, Brand N: Effect of add on amantadine therapy for refractory absence epilepsy. J Pediatr 1992; 121:819-821
26. Drake ME, Pakalnis A, Denio S, et al: Amantadine hydrochloride for refractory generalized epilepsy in adults. Acta Neurol Belg 1991; 91:159-164
27. Folstein MF, Folstein SE, McHugh P: "Mini-Mental State": a practical method for grading cognitive state of the patient for the clinician. J Psychiatr Res 1985; 12:189-198
28. Albert M, Cohen C: The Test for Severe Impairment: an instrument of the assessment of patients with severe cognitive dysfunction. J Am Geriatr Soc 1992; 40:449-453
29. Sunderland T, Hill JL, Mellow AM, et al: Clock drawing in Alzheimer's disease: a novel measure of dementia severity. J Am Geriatr Assoc 1989; 37:725-729
30. Brandt J: The Hopkins Verbal Learning Test: development of a new memory test with six equivalent forms. The Clinical Neuropsychologist 1991; 5:125-142
31. Schretlen D: Brief Test of Attention. Baltimore, MD, D Schretlen, 1989
32. Reitan RM, Wolfson D: The Halstead-Reitan Neuropsychological Test Battery. Tucson, AZ, Neuropsychology Press, 1985
33. Reitan RM, Wolfson D: Category Test and Trail Making Test as measures of frontal lobe functions. The Clinical Neuropsychologist 1995; 9:50-56
34. Benton AL: Differential behavioral effects in frontal lobe disease. Neuropsychologia 1968; 6:53-60
35. Wechsler D: Wechsler Memory Scale-Revised. New York, Psychological Corporation, 1987
36. Frith CD, Friston KJ, Liddle P, et al: A PET study of word finding. Neuropsychologia 1991; 29:1137-1148
37. Parks RW, Loewenstein DA, Dodrill KL, et al: Cerebral metabolic effects of a verbal fluency test: a PET scan study. J Clin Exp Neuropsychol 1988; 10:565-575
38. Warkentin S, Passant U: Frontal activation of the frontal lobes: regional cerebral blood flow findings in normals and in patient with frontal lobe dementia performing a word fluency test. Dementia 1993; 4:188-191
39. Wolfe N, Katz DI, Albert ML, et al: Neuropsychological profile linked to low dopamine: in Alzheimer's disease, major depression, and Parkinson's disease. J Neurol Neurosurg Psychiatry 1990; 53:915-917